Early Gains Alert! Top Picks Inside!

Don’t want emails from us anymore? Click here to unsubscribe

Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

  • Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

  • Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

  • Top Pre-Market Movers: Identify early winners poised for a strong market opening.

  • Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

  • FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.


We've just released a new special report that details the top 10 stocks to own now.

Some are delivering stellar earnings... others are at the forefront of an explosive trend... others dominate their industry. All offer tremendous opportunity no matter what the market does.

Get the full list here FREE

Happening Today

✓ 10:00 AM ET – FOMC Member Bostic Speaks

✓ 10:30 AM ET – Dallas Fed Mfg Business Index (Mar)

✓ 10:30 AM ET – Fed Governor Cook Speaks

✓ 01:00 PM ET – 2-Year Note Auction


Stocks are mixed today, with the NASDAQ leading the way with a gain of 0.1% while the S&P 500 and Dow Jones are down slightly.



⬇️ -0.14% 



⬇️ -0.77% 



⬆️ 0.16%


Today's market is a tale of two halves: Tech (+0.45%) and Communication Services (+0.85%) climb, whereas Financials (-1.21%) and Real Estate (-1.24%) decline.




Consumer Discretionary


-0.63% 🔴

Consumer Staples


-0.56% 🔴



-0.20% 🔴



-1.21% 🔴

Health Care


-0.14% 🔴



-0.34% 🔴



-0.59% 🔴

Real Estate


-1.24% 🔴

Information Technology


+0.45% 🟢

Communication Services


+0.85% 🟢



+0.15% 🟢


Billionaire Investors Join Forces to Fund Next Generation

There's now so much money to be made in this sector that billionaires and private equity investors are pouring billions of dollars into clean energy companies. For example, Jeff Bezos, Bill Gates, Richard Branson, Michael Bloomberg, Ray Dalio and many others have teamed up to invest more than $2 billion - with billions more to come.

Learn More

Unusual Volume

📈 Biolase Inc (BIOL) jumped 19.53% to $0.18 on a whopping 131.37 million shares traded.

📈 Investors went wild, sending Tilray Brands Inc (TLRY) stock soaring 18.46% to $2.31 on a massive volume of 96.07 million shares after the company released the expansion of Redecan's product portfolio with the launch of its latest genetics featuring Space Age Cake available in whole flower and its ‘Hemp’d’ pre-roll collection.

📈 Abnormal activity shook Faraday Future Intelligent Electric Inc (FFIE), pushing it down -3.16% to $0.13 on a whopping 76.01 million shares traded.

📈 Nova Lifestyle Inc (NVFY) stock recently closed 64.32% upper at $3.04 on substantial volume of 69.18 million shares.

📈 Canopy Growth Corporation (CGC) increase by 68.64% in a single trading session, with abnormally high trading volume of 67.0 million shares following the German government's final approval legalizing cannabis, as well as advancing a clear victory for enhanced medical cannabis access.


This DeFi Coin Could 10x Soon... I Advise You Get In Now!

Do NOT miss this opportunity for life-changing gains this year. Experts are predicting this coin has potential for unprecedented growth. Even a small position could deliver 10x returns or greater very soon. Timing is everything.

Discover this DeFi diamond before the next surge

Premarket Movers

MicroAlgo Inc. (MLGO) experiences a substantial 61.69% surge in pre-market trading, driven by the announcement of a pioneering deep clustering algorithm, with a pre-market price of $6.50 and a trading volume of 1.63 million shares.

Flora Growth Corp. (FLGC) sees a significant 36.70% increase, reaching a pre-market price of $2.16, alongside an update on Germany's cannabis legalization, with a trading volume of 1.60 million shares.

Salarius Pharmaceuticals, Inc. (SLRX) demonstrates a noteworthy 24.27% surge, with a pre-market price of $0.77 and a trading volume of 940.36 thousand shares, indicating investor confidence in its pharmaceutical advancements.

Pre Market Gainers

Pre Market Change

Pre Market Volume
































BREAKING: Elon Musk's Secret A.I. Project Set to Plunge Millions of Americans Into Poverty

Luke Lango, one of America's leading investors, just released shocking footage outside of the Tesla Gigafactory, in Austin, Texas. What's happening behind the scenes right here is set to change the course of humanity as we know it. McKinsey analysts are warning that the tech behind Elon Musk's new venture could throw 800 million workers worldwide into unemployment. Starting as early as this summer.  But, like all of Elon's projects, it will also mint many millionaires in the process. 

Click here now to prepare yourself for what's around the corner

Important FDA 

Recently Announced

Orchard Therapeutics plc (ORTX) achieved a significant breakthrough in pediatric medicine with the FDA's recent endorsement of its pioneering gene therapy, OTL-200, recognized as Lenmeldy. This approval, disclosed on March 18, 2024, marks a pivotal moment in the treatment of metachromatic leukodystrophy in children.

Meanwhile, OptiNose Inc. (OPTN) broadened the application of its innovative XHANCE nasal spray with the FDA granting approval on March 15, 2024, for its efficacy in managing chronic rhinosinusitis in adult patients. This expansion underscores OptiNose's commitment to addressing diverse medical needs through advanced nasal delivery solutions.

Upcoming this Week

Merck & Co Inc. (MRK) anticipates a pivotal moment as the FDA decision on Sotatercept, slated for March 26, 2024, looms. This decision holds immense significance for adult patients suffering from pulmonary arterial hypertension, with the potential to offer a new ray of hope in treatment.

Akebia Therapeutics, Inc. (AKBA) stands on the cusp of a significant milestone as the FDA decision on Vadadustat approaches on March 27, 2024. Vadadustat's resubmitted NDA holds promise as a potential remedy for anemia resulting from chronic kidney disease in adult patients undergoing dialysis.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Daily DigitalYour guide to passive income online. Discover opportunities for financial freedom, one email a day. 💸

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

 Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.